| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1213 | 2020 |
| Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, ... Journal of Clinical Oncology 38 (17), 1887, 2020 | 586 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 436 | 2021 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study K Tamura, J Tsurutani, S Takahashi, H Iwata, IE Krop, C Redfern, ... The Lancet Oncology 20 (6), 816-826, 2019 | 331 | 2019 |
| Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan Annals of surgery 265 (3), 581-589, 2017 | 313 | 2017 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 296 | 2021 |
| Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial N Masuda, Y Sagara, T Kinoshita, H Iwata, S Nakamura, Y Yanagita, ... The lancet oncology 13 (4), 345-352, 2012 | 215 | 2012 |
| Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ... JAMA surgery 150 (8), 739-745, 2015 | 195 | 2015 |
| Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based … Y Sagara, RA Freedman, I Vaz-Luis, MA Mallory, SM Wong, F Aydogan, ... Journal of Clinical Oncology 34 (11), 1190, 2016 | 152 | 2016 |
| Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer Y Sagara, K Mimori, K Yoshinaga, F Tanaka, K Nishida, S Ohno, H Inoue, ... British journal of Cancer 91 (5), 959-965, 2004 | 125 | 2004 |
| F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner K Yumimoto, S Akiyoshi, H Ueo, Y Sagara, I Onoyama, H Ueo, S Ohno, ... The Journal of clinical investigation 125 (2), 621-635, 2015 | 115 | 2015 |
| Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple‐negative breast cancer Y Ohi, Y Umekita, T Yoshioka, M Souda, Y Rai, Y Sagara, Y Sagara, ... Histopathology 59 (4), 776-780, 2011 | 108 | 2011 |
| Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. H Iwata, K Tamura, T Doi, J Tsurutani, S Modi, H Park, IE Krop, Y Sagara, ... Journal of Clinical Oncology 36 (15_suppl), 2501-2501, 2018 | 95 | 2018 |
| Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies AI Hida, Y Sagara, D Yotsumoto, S Kanemitsu, J Kawano, S Baba, Y Rai, ... Breast cancer research and treatment 158, 1-9, 2016 | 69 | 2016 |
| Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: a long‐term follow‐up study T Yoshioka, Y Umekita, Y Ohi, M Souda, Y Sagara, Y Sagara, Y Sagara, ... Histopathology 58 (4), 608-616, 2011 | 68 | 2011 |
| The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition T Shimoi, SE Nagai, T Yoshinami, M Takahashi, H Arioka, M Ishihara, ... Breast Cancer 27, 322-331, 2020 | 62 | 2020 |
| National patterns of breast reconstruction and nipple-sparing mastectomy for breast cancer, 2005–2015 SM Wong, YS Chun, Y Sagara, M Golshan, J Erdmann-Sager Annals of Surgical Oncology 26, 3194-3203, 2019 | 60 | 2019 |
| Identification of molecular markers for metastasis-related genes in primary breast cancer cells K Mimori, A Kataoka, K Yoshinaga, M Ohta, Y Sagara, Y Yoshikawa, ... Clinical & experimental metastasis 22, 59-67, 2005 | 57 | 2005 |
| Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. GHM Jerusalem, YH Park, T Yamashita, SA Hurvitz, S Modi, F Andre, ... Journal of Clinical Oncology 39 (15_suppl), 526-526, 2021 | 52 | 2021 |
| Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) M Takada, H Ishiguro, S Nagai, S Ohtani, H Kawabata, Y Yanagita, ... Breast cancer research and treatment 145, 143-153, 2014 | 47 | 2014 |
